Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences: Board member Merdad Parsey resigns; Dietmar Berger appointed Class II director

Neutral Impact 2 of 5 leadership Written later

Arcus Biosciences reported that Merdad Parsey resigned from its Board of Directors on February 6, 2025, in connection with his departure from Gilead Sciences. The Board the same day appointed Dietmar Berger, who joined Gilead in January 2025 as its Chief Medical Officer, as a Class II director to fill the vacancy; the filing says Gilead's board designee arrangement governs the timing of the change.

Key points

  • Merdad Parsey resigned from the Arcus Board, effective upon appointment of Gilead's new director designee under the Amended and Restated Investor Rights Agreement dated January 29, 2024.
  • Dietmar Berger was appointed as a Class II director on February 6, 2025.
  • Dr. Berger will receive no compensation for Board service; Arcus expects to enter its standard indemnification agreement with him.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECFeb 6, 2025, 5:02 PM ET
Accession number0001724521-25-000024

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.